Neurocrine Bioscienc (NBIX)
$132.54
0.69 (0.52%)
NBIX Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
13.08B
PE Ratio
54.32
EPS
2.44
Volume (Avg. Vol.)
586,541
Day's Range
$131.00 - $134.20
52-Week Range
$89.04 - $148.37
Dividend & Yield
N/A (N/A)
NBIX Stock Predictions, Articles, and Neurocrine Bioscienc News
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.
7 Beautiful Biotech Stocks to Buy Here
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Neurocrine Biosciences Is a Pharma Stock to Watch
Biopharma company Neurocrine isn't letting a setback with one of its drugs stop it. Here's what to know about NBIX stock.
3 Stocks to Watch on Wednesday: Tesla, Inc. (TSLA), Delta Air Lines, Inc. (DAL) and Neurocrine Biosciences, Inc. (NBIX)
Delta Air Lines (DAL) pops on solid Q1 earnings, a major investor questions Tesla's (TSLA) board and Neurocrine Biosciences (NBIX) is flying on an FDA approval.
40 Biotechnology Stocks to Sell Now
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
40 Biotechnology Stocks to Sell Now
The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
52 Biotechnology Stocks to Sell Now
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
30 Biotechnology Stocks to Sell Now
The ratings of 30 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
26 Biotechnology Stocks to Sell Now
The ratings of 26 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
